

Attorney Docket No.: 10319.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE
(DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Mail Stop PCT
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

This is a request for filing a patent application under 35 U.S.C. 371 of the international application identified below:

INTERNATIONAL APPLICATION NO.		INTERNATIONAL FILING DATE
PCT/DK2003/000851		December 11, 2003
APPLICANT(S)/INVENTOR(S)		
First Name	Middle Name	Family Name
1. Leonardo 2. Allan 3. Torben 4. Lars 5. Sine 6. Carsten	1. 2. 3. Vedel 4. Lehmann Hylling 5. 6.	1. De Maria 2. Svendsen 3. Borchert 4. Christensen 5. Larsen 6. Ryttergaard
TITLE OF THE INVENTION		
Galactanase Variants		

1. This is a first submission of items concerning a filing under 35 U.S.C. 371.
2. This is an express request to begin national examination procedures (35 U.S.C. 371(f)).
3. The US has been elected.
4. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) has been communicated by the International Bureau

Specification	87 Pages
Abstract	1 Pages
Sequence Listing	14 Pages
Drawings	174 Pages
Total	276 Pages

5. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) have not been made and will not be made.
6. An application data sheet is enclosed.

7. Priority of Danish application nos. PA 2002 01968 and PA 2003 00537 filed on December 20, 2002 and April 8, 2003, respectively, is claimed under 35 U.S.C. 119(a)-(d).
8. The benefit of U.S. provisional application nos. 60/437,615 and 60/461,230 filed on January 2, 2003 and April 8, 2003, respectively, is claimed under 35 U.S.C. 119(e).
9. An oath or declaration of the inventors is submitted herewith.
10. An Information Disclosure Statement is submitted herewith.
11. An Assignment and Recordation Form Cover Sheet are submitted herewith.
12. A Preliminary Amendment is submitted herewith.
13. Applicants enclose a paper copy and a computer readable form of a Sequence Listing. The content of the paper copy and of the computer readable form is the same.
14. The assignee of the present application is:

Novozymes A/S
Krogshoejvej 36
DK-2880 Bagsvaerd
Denmark

Applicants request that the assignee information be included in the published patent application.

15. Direct all correspondence to Customer Number 25908.
16. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):

Basic Fee:	\$300.00
Examination Fee:	\$200.00
Search Fee:	\$500.00
Size Fee (\$250 for each 50 pages above 100)	\$1,000.00

CLAIMS FEE

Total Claims: 14- 20 = 0 x 50 =	\$0.00
Independent Claims: 1 - 3 = 0 x 200 =	\$0.00
Total Claims Fee:	\$0.00

FEE FOR RECORDING ASSIGNMENT	\$40.00
TOTAL NATIONAL FEE	\$2,040.00


10/537746

JC17 Rec'd PCT/PTO 06 JUN 2005

17. Please charge the required fee, estimated to be \$2,040, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: June 6, 2005



Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

10/557746
JC17 Rec'd PCT/PTO 06 JUN 2005
PATENT

Attorney Docket No. 10319.204-US

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

INTERNATIONAL APPLICATION NO.: PCT/DK2003/0000851

INTERNATIONAL FILING DATE: December 11, 2003

PRIORITY DATE: December 20, 2002

TITLE: Galactanase Variants

APPLICANT(S) FOR RO/US: De Maria et al.

EXPRESS MAIL CERTIFICATE

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Express Mail Label No. EL 988468529 US

Date of Deposit: June 6, 2005

I hereby certify that the following attached papers or fee

1. Transmittal Letter to the DO/EO/US (in duplicate)
2. Executed Combined Declaration and Power of Attorney
3. Application Data Sheet
4. Preliminary Amendment
5. Recordation Form Cover Sheet
6. Assignment
7. Paper Copy of Sequence Listing
8. Disk Containing Sequence Listing
9. Information Disclosure Statement
10. Form PTO/SB/08A
11. Copy of References

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the address indicated above.

Lourdes Randazzo
(Name of person mailing paper(s) or fee)

Lourdes Randazzo
(Signature of person mailing paper(s) or fee)

Mailing Address:

Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097